Epidermal growth factor: receptors in human fibroblasts and modulation of action by cholera toxin. 1973

M D Hollenberg, and P Cuatrecasas

Epidermal growth factor (EGF) stimulates both DNA and RNA synthesis in contact-inhibited human fibroblasts. Stimulation of DNA synthesis is observed at concentrations as low as 3 pM, is half-maximal at 70 pM, and is maximal at 300 pM EGF. The action of EGF is similar to that of fetal-calf serum, but is distinguished by the time-course of stimulation and by the ability of serum to stimulate further those cells maximally stimulated by EGF. Cells that synthesize DNA in response to physiological concentrations of EGF (10(-11) to 10(-10) M) are insensitive to physiological concentrations of insulin (10(-11) to 10(-10) M) and respond only minimally to very high concentrations of this hormone (10(-6) M). The biological activity of EGF is paralleled by binding of this peptide to fibroblasts in a specific and saturable manner; the dissociation constant is about 800 pM. The binding of EGF is unaffected by either insulin or cholera toxin. Cholera toxin inhibits the action of both EGF and serum. Suppression of DNA synthesis is observed at 0.02 pM toxin, and is maximal at about 2 pM. Cells treated with cholera toxin at these concentrations appear to be otherwise viable by several criteria. The stimulatory effects of EGF are also inhibited by theophylline and dibutyryl cyclic AMP separately or in combination. These observations indicate that fibroblasts possess receptors for EGF by biological and physicochemical criteria, and suggest that a similar if not identical peptide may be amongst those factors in sera which stimulate cell growth. The possibility is considered that EGF and cholera toxin modulate the ability of a cell to initiate polynucleotide synthesis by way of specific cell-surface interactions which in turn alter the levels of intracellular cyclic AMP.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D011119 Polynucleotides BIOPOLYMERS composed of NUCLEOTIDES covalently bonded in a chain. The most common examples are DNA and RNA chains. Polynucleotide
D011955 Receptors, Drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. Drug Receptors,Drug Receptor,Receptor, Drug
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003994 Bucladesine A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed) Dibutyryl Adenosine-3',5'-Monophosphate,Dibutyryl Cyclic AMP,(But)(2) cAMP,Bucladesine, Barium (1:1) Salt,Bucladesine, Disodium Salt,Bucladesine, Monosodium Salt,Bucladesine, Sodium Salt,DBcAMP,Dibutyryl Adenosine 3,5 Monophosphate,N',O'-Dibutyryl-cAMP,N(6),0(2')-Dibutyryl Cyclic AMP,AMP, Dibutyryl Cyclic,Adenosine-3',5'-Monophosphate, Dibutyryl,Cyclic AMP, Dibutyryl,Dibutyryl Adenosine 3',5' Monophosphate,Disodium Salt Bucladesine,Monosodium Salt Bucladesine,N',O' Dibutyryl cAMP,Sodium Salt Bucladesine

Related Publications

M D Hollenberg, and P Cuatrecasas
November 1986, Proceedings of the National Academy of Sciences of the United States of America,
M D Hollenberg, and P Cuatrecasas
August 1991, Research communications in chemical pathology and pharmacology,
M D Hollenberg, and P Cuatrecasas
December 1993, Endocrine research,
M D Hollenberg, and P Cuatrecasas
August 1986, The American journal of physiology,
M D Hollenberg, and P Cuatrecasas
April 2009, Molecular biology reports,
M D Hollenberg, and P Cuatrecasas
August 1990, The British journal of dermatology,
M D Hollenberg, and P Cuatrecasas
December 1980, Science (New York, N.Y.),
M D Hollenberg, and P Cuatrecasas
February 1987, The Journal of biological chemistry,
Copied contents to your clipboard!